Erlotinib/Tarceva belongs to the first generation of targeted drugs

Erlotinib (Erlotinib) is an oral, small molecule tyrosine kinase inhibitor (TKI) that specifically targets tumors with epidermal growth factor receptor (EGFR) mutations. According to the generational division of targeted drug development, erlotinib belongs to the first generation of EGFR-targeted drugs. The first generation EGFR-TKI is characterized by reversibly binding to the ATP binding site of EGFR, thereby inhibiting receptor kinase activity, blocking downstream signaling pathways, inhibiting tumor cell proliferation and inducing apoptosis. As a first-generation drug, erlotinib has pioneered a clinical treatment model for EGFR-mutated non-small cell lung cancer (NSCLC) and is an important milestone in the field of precision medicine in the field of lung cancer.

Although the first generationTKI has significant efficacy, there are also drug resistance problems. Common resistance mechanisms include the emergence of the T790M mutation, which causes disease progression in some patients after taking the drug for a period of time. It is this limitation that drives the development of second- and third-generation EGFR inhibitors. Second-generation drugs partially overcome drug resistance by irreversibly binding to family receptors such as EGFR and HER2, while third-generation drugs such as osimertinib specifically target the T790M mutation while reducing inhibition of wild-type EGFR and reducing side effects.

Erlotinib, as the first generationEGFR targeted drug, has been widely used around the world for more than ten years and has accumulated rich clinical experience. Its advantages include oral convenience, clear efficacy, and high response rate for patients with EGFR-sensitive mutations. Despite the challenges of drug resistance, it is still the preferred targeted therapy for many patients. Clinicians will comprehensively judge whether to use erlotinib based on the patient's EGFR mutation type, previous treatment history, and tolerance, or switch to second- or third-generation EGFR-TKI after resistance occurs, so as to expand the therapeutic effect.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib